| Target Price | $262.65 |
| Price | $177.17 |
| Potential | 48.25% |
| Number of Estimates | 41 |
| 41 Analysts have issued a price target Arm 2027 . The average Arm target price is $262.65. This is 48.25% higher than the current stock price. The highest price target is $451.50 154.84% , the lowest is $126.25 28.74% . | |
| A rating was issued by 48 analysts: 30 Analysts recommend Arm to buy, 16 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Arm stock has an average upside potential 2027 of 48.25% . Most analysts recommend the Arm stock at Purchase. |
46 Analysts have issued a sales forecast Arm 2027 . The average Arm sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
30 Analysts have issued an Arm EBITDA forecast 2027. The average Arm EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
46 Arm Analysts have issued a net profit forecast 2027. The average Arm net profit estimate is
. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .This results in the following potential growth metrics and future Net Margins:
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Nov 05 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Nov 05 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Nov 05 2026 |
| UBS |
Buy
➜
Buy
|
Unchanged | Nov 05 2026 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Nov 05 2026 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Nov 05 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Nov 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Nov 05 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Nov 05 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Nov 05 2026 |
|
Unchanged
UBS:
Buy
➜
Buy
|
Nov 05 2026 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Nov 05 2026 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Nov 05 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Nov 05 2026 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


